AbbVie (ABBV) Q1 2024: Ex-Humira Platform Surges 15%, Offsetting Biosimilar Erosion

April 26, 2024 | By EarningsIQ Research

AbbVie’s diversified portfolio momentum, led by ex-Humira growth of 15%, countered biosimilar headwinds and supported an upward guidance revision. Management’s strategic focus on immunology, neuroscience, and oncology assets is translating into operational outperformance, while the company navigates leadership transition and formulary pressures. Investors should watch for continued pipeline execution and margin expansion as the Humira era winds down and new growth engines scale.

Summary

• Immunology Outperformance: Skyrizi and Rinvoq growth outpaces expectations, driving portfolio diversification.
• Margin and Pipeline Strength: Operating leverage and R&D productivity support resilient earnings despite Humira erosion.
• Transition Execution: Leadership handoff and recent M&A reinforce long-term growth trajectory beyond legacy blockbusters.

Business Overview

AbbVie is a global biopharmaceutical company generating revenue through branded prescription drugs across immunology, oncology, neuroscience, and aesthetics. Its business model centers on developing, marketing, and acquiring innovative therapies, with major segments including Immunology (Skyrizi, Rinvoq, Humira), Oncology (Venclexta, Imbruvica, Elahere), Neuroscience (Vraylar, Qulipta, Ubrelvy), and Aesthetics (Botox, Juvederm). The company is transitioning from dependence on Humira, its historic blockbuster, toward a more diversified, innovation-driven portfolio.

Performance Analysis

AbbVie delivered operational revenue growth of 1.6% in Q1, outpacing expectations by $400 million, propelled by a 15% increase from its ex-Humira growth platform. Immunology remains the largest segment, with Skyrizi and Rinvoq both posting combined year-over-year sales growth above 50%, and Skyrizi alone exceeding $2 billion in quarterly sales. Neuroscience and oncology also contributed double-digit revenue gains, with robust performances from Vraylar, Qulipta, and Venclexta. The aesthetics portfolio saw a modest operational decline, impacted by seasonality and inventory timing, but underlying market share for Botox and Juvederm remained stable.

Humira global sales declined 35% operationally due to biosimilar entry, but the erosion was largely price-driven and in line with guidance. Management highlighted that the majority of Humira’s remaining patient access is at parity with biosimilars, and volume impact from major formulary changes (notably CVS) was anticipated. The company’s operating margin held steady, with R&D investment at 14.7% of sales, supporting continued pipeline advancement.

• Immunology Leadership: Skyrizi is now the clear psoriasis market leader in the U.S., and Rinvoq is capturing share across approved indications.
• Oncology Pipeline Expansion: Integration of ImmunoGen and Elahere’s full FDA approval are strengthening AbbVie’s solid tumor franchise.
• Neuroscience Acceleration: Vraylar and the migraine portfolio (Qulipta, Ubrelvy) are gaining share, fueling segment growth above expectations.

Overall, AbbVie’s diversified portfolio and operational discipline enabled it to absorb Humira’s steep decline while raising full-year guidance.

Executive Commentary

Strategic Positioning

1. Immunology Franchise Transformation

AbbVie’s strategic pivot away from Humira dependence is anchored in the rapid adoption of Skyrizi and Rinvoq, both of which are demonstrating best-in-class efficacy and capturing substantial market share in psoriasis, Crohn’s disease, and atopic dermatitis. The company is preparing for further label expansions, notably Skyrizi in ulcerative colitis, which is expected to be a multi-billion dollar opportunity and further entrench AbbVie’s immunology leadership.

2. Oncology Pipeline and M&A Integration

The acquisition of ImmunoGen and pending Cerevel transaction are key to AbbVie’s oncology and neuroscience future. Elahere’s full FDA approval for platinum-resistant ovarian cancer and the integration of ImmunoGen’s talent signal a focused push into solid tumors, while Cerevel’s differentiated neuroscience assets are expected to close mid-year, augmenting the company’s portfolio breadth.

3. Neuroscience and Migraine Portfolio Scaling

Vraylar, Qulipta, and Ubrelvy are driving double-digit growth in neuroscience, with market share gains in major depressive disorder, bipolar I, and migraine prevention/treatment. The launch of Vialev for advanced Parkinson’s disease is on track, and upcoming Cerevel assets will further diversify the segment.

4. Aesthetics Market Resilience and Innovation

Despite a modest Q1 decline, the Allergan Aesthetics franchise remains the clear leader in facial injectables. Management attributed the softness to inventory timing and seasonality, with expectations for normalization in Q2 and resumed high single-digit growth for the year. Pipeline launches like Juvederm Voluma XC and Bonti (short-acting toxin) are positioned to expand the addressable market.

5. Margin Management and Capital Allocation

AbbVie is maintaining disciplined R&D and SG&A spending while absorbing increased interest expense from recent deals. Operating margin expansion is expected to be a tailwind beyond 2025, with the company guiding for robust earnings growth as portfolio mix improves and integration synergies are realized.

Key Considerations

This quarter, AbbVie demonstrated that its multi-year diversification strategy is yielding tangible results, even as Humira’s erosion continues and macro headwinds persist in certain geographies.

Key Considerations:

• Ex-Humira Growth Platform Momentum: Robust uptake of Skyrizi and Rinvoq is offsetting Humira declines and supporting upward guidance revisions.
• Pipeline Execution: Multiple late-stage readouts and regulatory milestones in immunology, oncology, and neuroscience are expected in 2024, sustaining long-term growth visibility.
• Formulary and Contracting Dynamics: Management anticipates Humira access parity for most patients through 2024, with volume and price erosion largely as modeled, but future payer moves remain a watchpoint.
• Aesthetics Recovery: U.S. facial injectable market share is stable; international growth is pressured by China macro but expected to recover in H2 2024.
• Leadership Transition: The CEO handoff to Rob Michael is occurring from a position of operational strength, with a clear emphasis on continuity and execution.

Risks

AbbVie faces several risks as it transitions beyond Humira, including further biosimilar penetration, potential formulary exclusions, and regulatory headwinds from IRA Part D redesign in 2025. Macroeconomic softness in China continues to weigh on international aesthetics, and integration of recent acquisitions must deliver expected synergies without operational disruption. Competitive intensity in immunology, oncology, and neuroscience also remains high, with pipeline execution and payer dynamics representing ongoing variables.

Forward Outlook

For Q2 2024, AbbVie guided to:

• Net revenues of approximately $14 billion, reflecting stepped-up Humira volume erosion due to CVS formulary changes, partially offset by a one-time price benefit
• Adjusted operating margin ratio of approximately 49.5%
• Adjusted EPS between $3.05 and $3.09

For full-year 2024, management raised guidance:

• Adjusted EPS between $11.13 and $11.33 (up $0.16 at midpoint)
• Total net revenues of approximately $55 billion (up $800 million), driven entirely by ex-Humira growth

Management emphasized strong ex-Humira platform momentum, expected rapid recovery in aesthetics, and a pipeline rich with late-stage data and regulatory events. Key watchpoints include formulary dynamics, integration of ImmunoGen and Cerevel, and macro recovery in China.

• Volume and price erosion in Humira remain as modeled, with no major new exclusionary actions anticipated in 2024
• Operating margin expansion and robust revenue growth are expected to accelerate in 2026 and beyond

Takeaways

AbbVie’s Q1 results confirm that the ex-Humira growth platform is scaling rapidly enough to absorb biosimilar headwinds and support upwardly revised guidance.

• Growth Drivers: Skyrizi, Rinvoq, neuroscience, and oncology are now the core engines, with operational execution and pipeline delivery supporting confidence in AbbVie’s long-term outlook.
• Strategic Focus: M&A integration, operational discipline, and innovation in aesthetics and immunology are critical levers as the company navigates the Humira LOE trough.
• Investor Watchpoints: Track margin expansion, payer/contracting trends, China recovery, and late-stage pipeline milestones as indicators of AbbVie’s ability to sustain a high single-digit revenue CAGR through the decade.

Conclusion

AbbVie’s Q1 2024 performance underscores a successful pivot from legacy concentration to a diversified growth model, with immunology, neuroscience, and oncology now driving the narrative. While Humira erosion remains a near-term drag, robust execution, pipeline progress, and margin management position AbbVie for renewed growth and resilience in the post-Humira era.

Industry Read-Through

AbbVie’s results highlight the critical importance of portfolio diversification and pipeline execution for large-cap biopharma navigating major loss of exclusivity events. The company’s ability to offset steep legacy declines with new product growth and disciplined capital allocation is a relevant template for peers facing similar patent cliffs. The immunology market remains highly competitive, with rapid share shifts favoring best-in-class efficacy and label expansion, while payer and formulary dynamics continue to shape revenue trajectories for both branded and biosimilar entrants. Aesthetics recovery and China macro softness are industry-wide themes, and the success of M&A-driven pipeline enhancement will be a key differentiator across the sector in 2024 and beyond.

ABBV Healthcare Pharmaceuticals Immunology Oncology Neuroscience Aesthetics Pipeline